Endocrine Abstracts

Objective: Acromegaly has an important impact on health-related quality of life. The aim of study was to ascertain the quality of life of patients with uncontrolled vs controlled acromegaly and compared to those with non-functioning adenomas and healthy control group.

Methods: 124 participants underwent a cross-sectional assessment including the quality of life (AcroQoL, WHOQoL BREF), psychiatric morbidity (GHQ-28) and acceptance of illness (AIS). The sample consists of patients with acromegaly divided into two subgroups accordingly to minimal GH concentration during the OGTT or profile of GH and level of IGF1: controlled and cured acromegaly group (CAG n=19) and active acromegaly group (AAG n=31); patients with non-functioning adenomas group (NAG n=37) and healthy control group (CG n=37) matched according to age.

Results: No significant differences were identified between CAG, AAG and NAG groups referring to quality of life, psychiatric morbidity and acceptance of illness. Compared with healthy controls, AAG group suffered more from anxiety and insomnia (P=0.031) and had significantly poorer quality of life in psychological domain measured with WHOQoL BREF (P=0.004). In acromegaly group we observed statistically significant positive correlation between the level of IGF1 and prevalence of psychopathological symptoms measured by the GHO-28. We also observed negative correlation with the level of GH and AcroQoL in total score as well as in psychological dimension, including subscale ‘appearance’. The illness duration since diagnosis was identified as a negative predictor of physical dimension of AcroQoL (r=−0.35, P=0.035), social domain of WHOQoL (r=−0.43, P=0.009) and acceptance of the illness (r=−0.42, P=0.011).

Conclusion: Concerning the diagnosis, not only biochemical and radiological parameters, but also psychological aspect should be evaluated in acromegaly. IGF1 and GH could be an independent negative predictors of quality of life among those patients.

Disclosure: : Pbmn 118.